BeaCapra MK-677 Ibutamoren — Sustained Growth
Frequently Bought Together
MK-677 (Ibutamoren): Oral Growth Hormone Secretagogue
MK-677 (Ibutamoren Mesylate) is a non-peptide, orally active growth hormone secretagogue that mimics the GH-stimulating action of ghrelin. Unlike injectable peptide GH secretagogues, MK-677 is a small molecule with oral bioavailability, making it unique in the GH research landscape. Each bottle contains 25mg/mL in a 30mL solution, providing 750mg total compound at ≥99% purity, verified by HPLC.
Published clinical research on MK-677 includes studies in elderly populations, growth hormone-deficient subjects, and healthy volunteers. Studies have demonstrated sustained increases in GH and IGF-1 levels over extended administration periods without desensitization of the GH axis—a significant finding compared to exogenous GH administration.
MK-677's oral bioavailability and extended half-life (approximately 24 hours) have made it particularly valuable for research into chronic GH axis stimulation, sleep quality and architecture, nitrogen balance, and age-related changes in body composition and metabolic function.
Storage: Store at room temperature (15-25°C) in a cool, dry place. Protect from light. Once opened, use within 60 days.
For research use only. Not for human consumption. This product is not a drug, supplement, food, or cosmetic and may not be misbranded, misused, or mislabeled as such.
Research-Documented Benefits
- Oral GH Secretagogue — MK-677 (Ibutamoren) is a non-peptide, orally active ghrelin receptor agonist that increases GH pulsatility without injections.
- Sustained IGF-1 Elevation — Clinical research demonstrates persistent IGF-1 increases over months of administration without tachyphylaxis.
- Bone Density — Studies in elderly subjects and postmenopausal populations show improved markers of bone turnover and increased bone mineral density.
- Sleep Architecture — Research documents increased duration of REM sleep and stage IV (deep) sleep, correlating with enhanced nocturnal GH secretion.
- Nitrogen Retention — Short-term studies demonstrate improved nitrogen balance, a marker of protein synthesis and lean tissue preservation.
Mechanism of Action
MK-677 (Ibutamoren) is a non-peptide, orally active spiropiperidine compound that functions as a potent, selective agonist of the ghrelin receptor (GHS-R1a).
Primary Pathways
- Oral Ghrelin Mimetic — Unlike peptide-based secretagogues, MK-677 survives first-pass hepatic metabolism, providing oral bioavailability and sustained receptor activation over 24 hours.
- Pulsatile GH Amplification — Increases GH secretion by amplifying the amplitude of natural GH pulses without altering pulse frequency, maintaining physiological secretion patterns.
- Somatotroph Sensitization — Enhances pituitary sensitivity to GHRH, potentiating endogenous signaling rather than overriding it.
- IGF-1 Axis — Sustained GHS-R1a activation leads to persistent IGF-1 elevation, which does not undergo tachyphylaxis even after months of continuous administration.
MK-677's oral activity and sustained duration of action (effective half-life ~24 hours) provide unique advantages for chronic GH-axis research that would be impractical with injectable peptide secretagogues.
Research Protocol Guidelines
All protocols described are for in vitro and in vivo research purposes only. Not for human use.
Preparation
MK-677 (Ibutamoren) is typically supplied as an oral preparation (capsules or solution). No reconstitution required for oral formulations. For research solutions, dissolve in DMSO or PEG-400 for precise volumetric dosing.
Research Dosing (Published Clinical Literature)
- Standard research dose: 25 mg/day orally, administered once daily due to the extended effective half-life
- Dose range studied: 5-25 mg/day in clinical research protocols
- Duration: Studies range from 2 weeks (acute GH response) to 2 years (chronic IGF-1 and body composition studies)
- Timing: Evening administration in most studies to coincide with nocturnal GH secretion patterns
Storage
Store at room temperature (15-25°C) in a dry, light-protected environment. MK-677 is a stable non-peptide compound and does not require refrigeration or special handling.
Safety & Handling Information
For research use only. Not intended for human or veterinary diagnostic or therapeutic use.
Storage Requirements
- Store at room temperature (15-25°C), dry, light-protected
- No refrigeration required (non-peptide small molecule)
- Stable for 24+ months under proper storage conditions
Clinical Safety Data
MK-677 has been evaluated in multiple clinical studies lasting up to 2 years. The most commonly reported effects include increased appetite, transient edema, and muscle pain.
Known Considerations
- Insulin resistance: prolonged MK-677 administration may increase fasting blood glucose and reduce insulin sensitivity—monitor glucose in metabolic studies
- Edema and water retention may occur due to sustained GH elevation
- Appetite increase (ghrelin-mimetic) is consistent and may confound dietary studies
- Contraindicated in models with pre-existing diabetes or insulin resistance
- GH/IGF-1 neoplasia considerations apply for long-term studies
Handling
Standard laboratory PPE. No special handling required beyond standard small molecule precautions.
Frequently Asked Questions
Is MK-677 a peptide?
No. MK-677 (Ibutamoren) is a non-peptide spiropiperidine compound that is orally bioavailable. Unlike peptide secretagogues that require reconstitution and injection, MK-677 survives gastrointestinal and hepatic first-pass metabolism, providing sustained ghrelin receptor activation from an oral dose.
Does tolerance develop with chronic use?
Published clinical studies lasting up to 2 years show no tachyphylaxis (tolerance) of IGF-1 elevation. GH pulses remain elevated throughout chronic administration, which is unusual for receptor agonists and likely relates to the preserved pulsatile secretion pattern.
Why might insulin resistance be a concern?
GH is a counter-regulatory hormone that opposes insulin action. Sustained GH/IGF-1 elevation via chronic MK-677 use may increase fasting blood glucose and reduce insulin sensitivity, particularly in subjects with pre-existing metabolic vulnerability. Glucose monitoring is standard in MK-677 research protocols.
Can MK-677 be combined with peptide secretagogues?
While MK-677 and peptide GHRPs (GHRP-6, ipamorelin) act at the same receptor (GHS-R1a), co-administration is generally redundant. However, MK-677 may be combined with GHRH-class peptides (sermorelin, CJC-1295) for synergistic effects through complementary receptor pathways.
Related formulas
Customer Reviews
Exceptional purity and fast shipping
Third-party COA verified at 99.1% purity. Arrived in 2 days with proper cold packaging. The documentation included was thorough and professional. Will be ordering again for our lab.
Best supplier I've found
After trying several suppliers, BeaCapra consistently delivers the highest quality compounds. The subscribe & save option is a great value, and their customer support team answered all my questions promptly.
Great product, COA checks out
Ran our own HPLC analysis and confirmed the purity claims. Packaging was secure and discreet. Only minor note — would love to see more size options for some of the newer compounds. Otherwise excellent.
Subscribe & save is the way to go
The 15% discount on subscription makes this the most competitive pricing I've found for research-grade compounds at this purity level. Auto-delivery every 30 days has been seamless. Highly recommend.
Exactly what our research team needed
We've been sourcing from BeaCapra for our university lab and the consistency batch-to-batch is impressive. Every order comes with a COA and the compounds are properly lyophilized. Professional operation all around.
Questions About BeaCapra MK-677 Ibutamoren — Sustained Growth
General Questions
Everything you need to know about BeaCapra research peptides, ordering, shipping, and our commitment to quality.
Still have questions? Our research specialists are here to help.
Contact Us